In vitro effects of sulfadiazine and its metabolites alone and in combination with pyrimethamine on Toxoplasma gondii

Sulfadiazine and the metabolites N4-acetyl-sulfadiazine, 4-OH-sulfadiazine, 5-OH-sulfadiazine, 5-OH-glucuronide-sulfadiazine, and 5-OH-sulfate-sulfadiazine were tested separately and in combination with pyrimethamine for the inhibitory activity on Toxoplasma gondii growth in vitro. Except for N4-acetyl-sulfadiazine, all sulfa compounds possessed anti-Toxoplasma activity. The addition of 0.05 micrograms of pyrimethamine per ml, a concentration which in itself is not inhibitory, potentiated the microbial activity of sulfadiazine and its metabolites 100 fold.

[1]  T. Vree,et al.  Study of treatment of congenital Toxoplasma gondii infection in rhesus monkeys with pyrimethamine and sulfadiazine , 1995, Antimicrobial agents and chemotherapy.

[2]  L. Sibley,et al.  Toxoplasma gondii: analysis of different laboratory stocks of the RH strain reveals genetic heterogeneity. , 1994, Experimental parasitology.

[3]  B. Luft,et al.  Pyrimethamine concentrations in serum during treatment of acute murine experimental toxoplasmosis. , 1992, The American journal of tropical medicine and hygiene.

[4]  T. Vree,et al.  Novel oxidative pathways of sulphapyridine and sulphadiazine by the turtle Pseudemys scripta elegans. , 1991, The Veterinary quarterly.

[5]  C. Chastang,et al.  In vitro effects of folate inhibitors on Toxoplasma gondii , 1989, Antimicrobial Agents and Chemotherapy.

[6]  H. R. Chang,et al.  In vitro effects of three new 1,2,4-trioxanes (pentatroxane, thiahexatroxane, and hexatroxanone) on Toxoplasma gondii , 1989, Antimicrobial Agents and Chemotherapy.

[7]  T. Vree,et al.  Pharmacokinetics, metabolism, and renal clearance of sulfadiazine, sulfamerazine, and sulfamethazine and of their N4-acetyl and hydroxy metabolites in calves and cows. , 1988, American journal of veterinary research.

[8]  J. Kovacs,et al.  Potent antipneumocystis and antitoxoplasma activities of piritrexim, a lipid-soluble antifolate , 1988, Antimicrobial Agents and Chemotherapy.

[9]  T. Vree,et al.  Pharmacokinetics and renal clearance of sulfamethazine, sulfamerazine, and sulfadiazine and their N4-acetyl and hydroxy metabolites in horses. , 1987, American journal of veterinary research.

[10]  R. McLeod,et al.  New micromethod to study the effect of antimicrobial agents on Toxoplasma gondii: comparison of sulfadoxine and sulfadiazine individually and in combination with pyrimethamine and study of clindamycin, metronidazole, and cyclosporin A , 1984, Antimicrobial Agents and Chemotherapy.

[11]  J. Klein,et al.  Infectious Diseases of the Fetus and Newborn Infant , 1983 .

[12]  L. Barton.  Infectious Diseases of the Fetus and New-born Infant , 1977 .

[13]  L. Goodman,et al.  The Pharmacological Basis of Therapeutics , 1976 .

[14]  M. L. Melton,et al.  Effect of pyrimethamine and sulfadiazine on the fine structure and multiplication of Toxoplasma gondii in cell cultures. , 1975, The Journal of parasitology.

[15]  A. C. Bratton,et al.  A NEW COUPLING COMPONENT FOR SULFANILAMIDE DETERMINATION , 1939 .

[16]  H. Tanowitz,et al.  In vitro assessment of antimicrobial agents against Toxoplasma gondii. , 1988, The Journal of infectious diseases.

[17]  T. Vree,et al.  In vitro antimicrobial activity of hydroxy and N4-acetyl sulphonamide metabolites. , 1985, The Veterinary quarterly.

[18]  T. Vree,et al.  Pharmacokinetics of sulfonamides revisited. , 1985 .

[19]  John E. Bennett,et al.  Principles and practice of infectious diseases. Vols 1 and 2. , 1979 .